

Estimating treatment uptake for chronic hepatitis B infection across Australia

Jennifer MacLachlan¹
 Nicole Allard¹
 Benjamin Cowie^{1,2}

1. Epidemiology Unit VIDRL, The Doherty Institute, University of Melbourne
 2. Victorian Infectious Diseases Service, Royal Melbourne Hospital



Background: CHB burden of disease

- 218,000 Australians living with CHB in 2011¹; liver cancer fastest increasing cause of cancer death²
- Treatment reduces risk of liver failure and liver cancer³, and is cost-effective⁴
- 15-25% of people with CHB would benefit from treatment, on average


National Strategy Target: 15% uptake by 2017

1. MacLachlan 2013 2. AIHW 2012 3. Papatheodoridis 2010 3. Robotin 2009



Treatment for CHB in Australia

- 5 oral antivirals available and funded; also pegylated interferon
 - Entecavir and Tenofovir first line¹
- Subsidised for those who require treatment, based on disease criteria
- Provided through the PBS if Medicare eligible
- Data collected at a national level, reported according to state and territory



1. ASHM B Positive Guide for Primary Care Providers 2014



Data sources

	Publicly available Highly Specialised Drug Program expenditure data	Patient-level data obtained from Medicare Australia
Availability	Public (web) ¹	Purchased (data request)
Geographic specificity	State and Territory	+ Medicare Local
Data complete	mid 2010 onwards	mid 2013 onwards
Method of estimation	Extrapolating patients based on cost per script ¹	Patient level data derived using Medicare number
Used for	State and Territory estimates, trends over time	Medicare Local estimates, supplementary information

- Proportion of people with CHB receiving treatment estimated
- CHB data based on previously published estimates² by state and territory

1. Available at pbs.gov.au 2. MacLachlan 2013




Treatment expenditure and uptake, 2012

- HSD Expenditure on HBV antivirals: \$43 million in 2012
 - 3.6% of total HSD expenditure
- An estimated 10,987 Australians receiving HBV antiviral therapy in 2012
 - Increased 15% from 2011 (9,640)
- Represents 5% of the 218,000 living with CHB in 2011
 - Target is 15% by 2017

Source: HSD Expenditure data




State and Territory variation in treatment uptake, 2012




Source: HSD Expenditure data

Drug utilization trends, 2010-2012



Medicare Local data

- 11,000 Australians receiving therapy in 2012:
Around *half* estimated to reside in just 5 Medicare Locals, all in metropolitan Melbourne and Sydney



Strengths and limitations

- Routinely collected data
- Estimates include all scripts provided through Medicare
- Uptake estimated according to CHB data
- Indications for treatment related to disease stage, age, background, other risk factors
- Specificity



Conclusions

- Treatment for CHB is available and effective
- Current estimates indicate only a third of those who would benefit are receiving therapy
- Uptake varies by state and territory
- Treatment uptake is a National Strategy target
 - Measurement is essential
 - Data should be responsive, available, specific
 - Adopt responses to guide further intervention



Acknowledgements

The Hepatitis B Mapping Project is supported by an Australian Government Department of Health Communicable Diseases Flexible Fund Grant to ASHM and VIDRL

- particular thanks to Vanessa Towell, Program Manager, ASHM

Additional support for data procurement and analysis obtained via a Melbourne Health Home Lottery Early Career Grant-in-Aid to JM

Data sources:

Medicare Australia

Australian Bureau of Statistics

